Relationship between talimogene laherparepvec and intratumoral CD8+density in patients with unresectable stage IIIB-IVM1c melanoma: Interim efficacy, safety and biomarker results of a Phase 2 study

被引：0
|
作者：
Malvehy, J. [1 ,2 ]
Samoylenko, I. [3 ]
Schadendorf, D. [4 ]
Gutzmer, R. [5 ]
Grob, J. -J. [6 ,7 ]
Sacco, J. [8 ]
Gorski, K. S. [9 ]
Pickett, C. A. [9 ]
Liu, K. [9 ]
Gogas, H. [10 ]
机构：
[1] Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain
[2] Hosp Clin Barcelona, iDIBAPS, Barcelona, Spain
[3] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[4] Univ Duisburg Essen, Dept Dermatol, Essen, Germany
[5] Hannover Med Sch, Skin Canc Ctr Hannover, Hannover, Germany
[6] Aix Marseille Univ, Marseille, France
[7] APHM Timone, Marseille, France
[8] Clatterbridge Canc Ctr, Liverpool, Merseyside, England
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
[10] Univ Athens, Sch Med, Laiko Gen Hosp, Dept Med 1, Athens, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2017年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FC2.6
引用
收藏
页码：39 / 40
页数：2
相关论文
共 23 条
  • [1] Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma
    Chesney, Jason
    Awasthi, Sanjay
    Curti, Brendan
    Hutchins, Laura
    Linette, Gerald
    Triozzi, Pierre
    Tan, Marcus C. B.
    Brown, Russell E.
    Nemunaitis, John
    Whitman, Eric
    Windham, Christopher
    Lutzky, Jose
    Downey, Gerald F.
    Batty, Nicolas
    Amatruda, Thomas
    MELANOMA RESEARCH, 2018, 28 (01) : 44 - 51
  • [2] Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
    Stahlie, Emma H. A.
    Mulder, Evalyn E. A. P.
    Reijers, Sophie
    Balduzzi, Sara
    Zuur, Charlotte L.
    Klop, Willem M. C.
    van der Hiel, Bernies
    Van de Wiel, Bart A.
    Wouters, Michel W. J. M.
    Schrage, Yvonne M.
    Houdt, Winan J. van
    Grunhagen, Dirk J.
    Akkooi, Alexander C. J. van
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 175
  • [3] MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)
    Ribas, A.
    Chesney, J.
    Long, G. V.
    Kirkwood, J. M.
    Dummer, R.
    Puzanov, I.
    Hoeller, C.
    Gajewski, T. F.
    Gutzmer, R.
    Rutkowski, P.
    Demidov, L.
    Arenberger, P.
    Shin, S. J.
    Ferrucci, P. F.
    Diede, S. J.
    Anderson, J. R.
    Treichel, S.
    Chan, E.
    Hodi, F. S.
    Gogas, H. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S868 - S869
  • [4] LONG-TERM ANALYSIS OF MASTERKEY-265 PHASE 1B TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) PLUS PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE STAGE IIIB-IVM1C MELANOMA
    Long, Georgina
    Dummer, Reinhard
    Johnson, Douglas
    Michielin, Olivier
    Martin-Algarra, Salvador
    Treichel, Sheryl
    Chan, Edward
    Diede, Scott
    Ribas, Antoni
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A261 - A261
  • [5] Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma
    Malvehy, Josep
    Samoylenko, Igor
    Schadendorf, Dirk
    Gutzmer, Ralf
    Grob, Jean-Jacques
    Sacco, Joseph J.
    Gorski, Kevin S.
    Anderson, Abraham
    Pickett, Cheryl A.
    Liu, Kate
    Gogas, Helen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
  • [6] Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
    Harrington, Kevin J.
    Andtbacka, Obert H. I.
    Collichio, Frances
    Downey, Gerald
    Chen, Lisa
    Szabo, Zsolt
    Kaufman, Howard L.
    ONCOTARGETS AND THERAPY, 2016, 9 : 7081 - 7093
  • [7] Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB-IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study
    Gogas, H.
    Samoylenko, I.
    Schadendorf, D.
    Gutzmer, R.
    Grob, J. J.
    Sacco, J. J.
    Gorski, K.
    Anderson, A.
    Liu, C.
    Malvehy, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 443 - 443
  • [8] Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
    Chesney, J.
    Collichio, F.
    Andtbacka, R. H. I.
    Puzanov, I.
    Glaspy, J.
    Milhem, M.
    Hamid, O.
    Cranmer, L.
    Saenger, Y.
    Ross, M.
    Chen, L.
    Kim, J. J.
    Kaufman, H. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Interim Analysis of a Randomized, Open-Label Phase II Study of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery versus Surgery for Resectable Stage IIIB-IVM1a Melanoma
    Andtbacka, R.
    Dummer, R.
    Gyorki, D. E.
    Berger, A. C.
    Demidov, L.
    Chan, E.
    Treichel, S. A.
    Faries, M. B.
    Ross, M. I.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S6 - S6
  • [10] Response rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB-IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials
    Gogas, H.
    Gutzmer, R.
    Malvehy, J.
    Mehnert, J. M.
    Liu, K.
    Pickett, C. A.
    Snyder, W.
    Chesney, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 21 - 21
123